文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症创伤与烧伤

免疫分析揭示不同病因严重损伤患者延迟获得性免疫缺陷的共同免疫特征

Immune Profiling Demonstrates a Common Immune Signature of Delayed Acquired Immunodeficiency in Patients With Various Etiologies of Severe Injury.
PubMed 文献 · Crit Care Med · 2022-01-01
一句话结论严重损伤(脓毒症、创伤、手术)后第一周末持续存在深度免疫改变的患者继发感染风险增加,与侵入性装置暴露无关。

结果显示脓毒症、创伤和手术患者之间免疫特征无特异性,共同损伤诱导的免疫反应表现为初始适应性反应(涉及所有免疫系统成分),但与继发感染风险增加无关;相反,部分患者在第一周末持续存在深度免疫改变与继发感染风险增加独立相关(与侵入性装置暴露无关)。联合监测促炎/抗炎、先天和适应性免疫反应标志物能更好富集继发感染风险患者。

要点

  • 脓毒症、创伤和手术患者免疫特征无病因特异性,表现为共同损伤诱导的免疫反应。
  • 初始适应性免疫反应(涉及促炎/抗炎细胞因子、先天和适应性免疫)不增加继发感染风险。
  • 第一周末持续深度免疫改变与继发感染风险增加独立相关,与侵入性装置暴露无关。
  • 联合监测促炎/抗炎、先天和适应性免疫标志物可更好富集继发感染风险患者。
  • 免疫监测需纳入更大研究队列以开发特定假设,识别影响急性全身损伤后晚期感染相关免疫功能的生物系统。

适用人群与场景

  • 成人ICU的脓毒症、创伤和手术患者;排除人群原文未提及。
  • 研究场景为法国里昂大学医院成人ICU;病情阶段为入组后第1-2天、3-4天和5-7天。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 第一周末(第5-7天)持续存在深度免疫改变的患者继发感染风险增加,需关注。

研究设计与关键结果

  • 使用30种标准化免疫标志物在入组后第1-2天、3-4天和5-7天进行免疫分析,脓毒症、创伤和手术患者间免疫特征无特异性。
  • 共同损伤诱导的免疫反应表现为初始适应性反应(促炎和抗炎细胞因子释放、先天和适应性免疫反应),但不与继发感染风险增加相关。
  • 部分患者第一周末持续深度免疫改变与继发感染风险增加独立相关(与侵入性装置暴露无关)。
  • 联合监测促炎/抗炎、先天和适应性免疫反应标志物能更好富集继发感染风险患者。

证据类型、等级与局限

  • 证据类型为前瞻性观察性队列研究;原文未给出证据等级或推荐强度。
  • 局限:单中心研究;原文未提及样本量计算、盲法等其他局限。

对床旁实践的改变

  • 对严重损伤(脓毒症、创伤、手术)患者,可在第一周末通过联合监测促炎/抗炎、先天和适应性免疫标志物识别持续深度免疫改变者,这类患者继发感染风险增加。
  • 免疫监测目前尚需在更大研究队列中验证以开发特定假设,不能仅凭此改变常规实践。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

OBJECTIVES: The host response plays a central role in the pathophysiology of sepsis and severe injuries. So far, no study has comprehensively described the overtime changes of the injury-induced immune profile in a large cohort of critically ill patients with different etiologies.

DESIGN: Prospective observational cohort study.

SETTING: Adult ICU in a University Hospital in Lyon, France.

PATIENTS: Three hundred fifty-three septic, trauma, and surgical patients and 175 healthy volunteers were included in the REAnimation Low Immune Status Marker study.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: Extensive immune profiling was performed by assessing cellular phenotypes and functions, protein, and messenger RNA levels at days 1-2, 3-4, and 5-7 after inclusion using a panel of 30 standardized immune markers. Using this immunomonitoring panel, no specificity in the immune profile was observed among septic, trauma, and surgical patients. This common injury-induced immune response was characterized by an initial adaptive (i.e., physiologic) response engaging all constituents of the immune system (pro- and anti-inflammatory cytokine releases, and innate and adaptive immune responses) but not associated with increased risk of secondary infections. In contrary, the persistence in a subgroup of patients of profound immune alterations at the end of the first week after admission was associated with increased risk of secondary infections independently of exposure to invasive devices. The combined monitoring of markers of pro-/anti-inflammatory, innate, and adaptive immune responses allowed a better enrichment of patients with risk of secondary infections in the selected population.

CONCLUSIONS: Using REAnimation Low Immune Status Marker immunomonitoring panel, we detected delayed injury-acquired immunodeficiency in a subgroup of severely injured patients independently of primary disease. Critically ill patients' immune status could be captured through the combined monitoring of a common panel of complementary markers of pro-/anti-inflammatory, innate, and adaptive immune responses. Such immune monitoring needs to be incorporated in larger study cohorts with more extensive immune surveillance to develop specific hypothesis allowing for identification of biological systems affecting altered immune function related to late infection in the setting of acute systemic injury.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Venet F, Textoris J, Blein S, et al. Immune Profiling Demonstrates a Common Immune Signature of Delayed Acquired Immunodeficiency in Patients With Various Etiologies of Severe Injury. Crit Care Med. 2022. PMID: 34534131. doi:10.1097/CCM.0000000000005270

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。